Unacylated Ghrelin Does Not Acutely Affect Substrate Metabolism or Insulin Sensitivity in Men With Type 2 Diabetes

What Was Tested

Researchers studied Ghrelin in this randomized controlled trial publication.

The researchers therefore tested the effects of intravenous UAG infusion on glucose and lipid metabolism, insulin sensitivity, and energy expenditure in men with type 2 diabetes mellitus (T2DM).

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, men only.

The patients were investigated in the basal postabsorptive state for 4 hours, followed by a hyperinsulinemic clamp for 2 hours.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Ghrelin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Ghrelin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Ghrelin could be set against what happens without it.

Each person switched between Ghrelin and the comparison at some point, usually with a gap in between.

Randomized, double-blind, placebo-controlled crossover study performed at a university hospital clinical research center.

The turnover rates of glucose and fatty acids were assayed by isotope tracer techniques.

Energy expenditure was measured by indirect calorimetry.

What Was Measured

The subject headings attached to it are Acylation, Diabetes Mellitus, Type 2, Energy Metabolism, Ghrelin, Glucose, Insulin Resistance and Lipolysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Ghrelin compound page, all human trials.